| Autor: |
Alex C. Spyropoulos, Briain O. Hartaigh, Zhun Cao, Craig Lipkin, Scott B. Robinson, Harjeet Caberwal, Michaela Petrini, Cheng Wang |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Cardiology research. 13(1) |
| ISSN: |
1923-2829 |
| Popis: |
The objective of the study was to describe the healthcare resource utilization (HCRU) and associated costs with hospitalized patients receiving specific versus non-specific oral anticoagulation reversal therapy for life-threatening bleeds and emergency surgeries or urgent procedures.This retrospective observational study using the Premier Healthcare Database included adult patients aged ≥ 18 years treated with idarucizumab (IDA) or 3- or 4-factor prothrombin complex concentrates (PCC) to reverse the effects of dabigatran or warfarin, respectively, between October 2015 and February 2018.Median ages for IDA (n = 1,232) and PCC (n = 4,939) patients were 78 and 74 years (P0.001), respectively. IDA patients had lower bleeding and stroke risk assessment scores (HAS-BLED; P0.001 and CHAThis analysis revealed lower HCRU and total hospital costs in patients administered IDA compared with PCC for reversal of oral anticoagulation, though differences in population characteristics and bleeding events were observed that may have contributed to these findings. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
